Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II AK104 plus anlotinib in advanced non-small cell lung cancer
ChiCTR2000035993Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective response rate. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
cadonilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000035993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035993.